These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 24979706)
21. Statistical issues and recommendations for noninferiority trials in oncology: a systematic review. Tanaka S; Kinjo Y; Kataoka Y; Yoshimura K; Teramukai S Clin Cancer Res; 2012 Apr; 18(7):1837-47. PubMed ID: 22317762 [TBL] [Abstract][Full Text] [Related]
22. Sequential parallel comparison design with two coprimary endpoints. Homma G; Daimon T Pharm Stat; 2020 May; 19(3):243-254. PubMed ID: 31829521 [TBL] [Abstract][Full Text] [Related]
23. Gatekeeping testing via adaptive alpha allocation. Li JD; Mehrotra DV Biom J; 2008 Oct; 50(5):704-15. PubMed ID: 18932133 [TBL] [Abstract][Full Text] [Related]
24. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints. Guo B; Liu S Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481 [TBL] [Abstract][Full Text] [Related]
25. Designs of superiority and noninferiority trials for binary responses are noninterchangeable. Hilton JF Biom J; 2006 Dec; 48(6):934-47. PubMed ID: 17240653 [TBL] [Abstract][Full Text] [Related]
26. Blinded sample size recalculation in clinical trials with binary composite endpoints. Sander A; Rauch G; Kieser M J Biopharm Stat; 2017; 27(4):705-715. PubMed ID: 27295402 [TBL] [Abstract][Full Text] [Related]
27. Some controversial multiple testing problems in regulatory applications. Hung HM; Wang SJ J Biopharm Stat; 2009; 19(1):1-11; discussion 12-41. PubMed ID: 19127460 [TBL] [Abstract][Full Text] [Related]
28. Choice of delta noninferiority margin and dependency of the noninferiority trials. Tsong Y; Zhang J; Levenson M J Biopharm Stat; 2007; 17(2):279-88. PubMed ID: 17365224 [TBL] [Abstract][Full Text] [Related]
29. Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables. Sozu T; Sugimoto T; Hamasaki T Biom J; 2012 Sep; 54(5):716-29. PubMed ID: 22829198 [TBL] [Abstract][Full Text] [Related]
30. Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM. Hung HM; Wang SJ; O'Neill R J Biopharm Stat; 2007; 17(2):201-13. PubMed ID: 17365218 [TBL] [Abstract][Full Text] [Related]
31. Testing multiple primary endpoints in clinical trials with sample size adaptation. Liu Y; Hu M Pharm Stat; 2016; 15(1):37-45. PubMed ID: 26607410 [TBL] [Abstract][Full Text] [Related]
32. Use of composite endpoints in clinical trials. Sankoh AJ; Li H; D'Agostino RB Stat Med; 2014 Nov; 33(27):4709-14. PubMed ID: 24833282 [TBL] [Abstract][Full Text] [Related]
33. Consistency ensured test strategies for supportive evidence of treatment efficacy in noninferiority clinical trials. Huque M; Valappil T; Alosh M J Biopharm Stat; 2018; 28(1):1-14. PubMed ID: 29173026 [TBL] [Abstract][Full Text] [Related]
34. Note on simultaneous inferences about non-inferiority and superiority for a primary and a secondary endpoint. Guilbaud O Biom J; 2011 Nov; 53(6):927-37. PubMed ID: 22002473 [TBL] [Abstract][Full Text] [Related]
35. Frequentist evaluation of group sequential clinical trial designs. Emerson SS; Kittelson JM; Gillen DL Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678 [TBL] [Abstract][Full Text] [Related]